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Using visUal aides in tRanslation of a sPasticity syMPtoM 
qUestionnaiRe
Brandt  B.A1, Talbert M.2, McKown S.3, Gawlicki M.C.1, Bernardi K.3
1Corporate Translations, Inc., East Hartford, CT, USA, 2Corporate Translations Inc., Chicago, IL, 
USA, 3Corporate Translations, Inc., Chicago, IL, USA
Objectives: The objective of this study was to determine the effectiveness of visual 
aids for translation of the Spasticity Symptom Assessment-Upper Limb (SSA-UL) 
questionnaire as an additional support tool for linguists. Some items in the SSA-UL 
concern specific physical positions experienced by stroke patients, due to muscle 
spasticity. It was theorized that translation would be improved by providing transla-
tors with a visual of physical positions, supplementing a textual definition, which 
may be complex and open to varied interpretations. MethOds: The SSA-UL was 
translated into 14 languages. Translators were provided a textual definition and 
images of the following physical positions: (1) hand clenching, (2) finger clenching, 
(3)hand curling and (4) finger curling. Back-translations were analyzed for conceptual 
equivalency with the source text. In addition, each translator (n= 28) was given a 
questionnaire about the effectiveness of the visual aids. Results: Translations of 
hand clenching and finger clenching were conceptually equivalent to the source 100% 
of the time. For both hand and finger curling, only French-Canada and Polish-Poland 
struggled to find an equivalent translation, ultimately achieving a conceptually 
equivalent translation. German-Germany linguists had initially translated curling 
and clenching incorrectly, but utilized the images to revise the translation. Nineteen 
(19) linguists responded to the questionnaire. Fifteen (79%) found the visual aids 
helpful. For comparison, previous translations of other physical positions translated 
without visual aids were analyzed with a similar language sample. Bending was 
translated as conceptually equivalent to the source 83% (10/12) of the time, stooping 
58% (7/12) and feet dropping forwards 50% (6/12). cOnclusiOns: Back-translations 
showed that visual aids added value to the translation process. Linguists surveyed 
reported that the visual aids assisted them in finding the correct terminology for 
the physical positions. Moving forward, translation of questionnaires containing 
items about physical positions may benefit from visual aids.
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Objectives: A 12-week prospective, observational study was conducted to evaluate 
the psychometric properties of the Brief Fatigue Inventory-Short Form (BFI-SF) and 
determine its appropriate use and performance for the measurement of fatigue 
in systemic lupus erythematosus (SLE) clinical trials. MethOds: Participants ≥ 18 
years, who self-reported a physician diagnosis of SLE (confirmed by medical record 
review) and active SLE demonstrated by a Systemic Lupus Activity Questionnaire 
(SLAQ) score ≥ 11 (0-44 scale), were recruited using a free electronic medication 
monitoring service. All participants completed the BFI-SF, Multidimensional 
Assessment of Fatigue (MAF), and Short Form-36 (SF-36) electronically at baseline, 
week 2, and week 12. Score distributions, internal consistency, test-retest reliability, 
and construct validity were evaluated. Results: A total of 122 participants were 
included in the study. The mean age was 45.7 years, 95.9% were female, and 68.9% 
were non-Hispanic white. Cronbach’s alpha were > 0.9 for all BFI-SF items. Test-
retest reliability of the BFI-SF showed a stable intraclass correlation for item #7 (ICC 
0.76), and BFI domain scores had higher correlations (around 0.5) than most items 
(around 0.3-0.4). Construct validity was measured by strength of the correlations 
of the BFI-SF severity domains and global scores, and was moderately positively 
correlated to the SLAQ score (r> 0.4). The domain and global scores were moderately 
negatively correlated to the SF-36 Vitality and Physical Function domains and SF-36 
Physical Component score (r< -0.3). The BFI-SF item #3 for worst fatigue was highly 
positively correlated to the MAF (r= 0.6). Patients with less severe fatigue (MAF≤ 36) 
scored lower than patients with more severe fatigue (MAF> 36) on all domains of the 
BFI-SF (total score, 4.66±1.55 vs. 6.80±1.13; p< 0.0001). cOnclusiOns: Assessment 
of fatigue severity as measured by the BFI-SF demonstrated validity and reliability 
in a sample of patients with moderate-to-severe SLE and may be used as a patient-
reported outcome tool in clinical trials.
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Objectives: Patient-reported outcome (PRO) instruments commonly used to meas-
ure fatigue in multiple sclerosis (MS) have not been developed according to the 2009 
FDA PRO guidance. A qualitative research study was conducted to develop a new 
PRO, according to the guidance, measuring fatigue symptoms and impacts in relaps-
ing MS (RMS). MethOds: Adult patients with relapsing-remitting MS (RRMS) were 
interviewed to elicit fatigue-related symptoms and impacts. Based on spontaneously 
reported symptoms, a draft PRO was developed. This was debriefed in cognitive 
interviews with further RRMS patients, and subsequently revised. Applicability of 
the PRO to other RMS populations was determined in content confirmation inter-
views with progressive-relapsing MS (PRMS) and relapsing secondary-progressive 
MS (RSPMS) patients. Institutional review board approval and participant informed 
consent were obtained before interviews. Results: Participants were representative 
of RMS patients in clinical studies and practice; most had mild-to-moderate disease. 
Concept elicitation and cognitive debriefing included 17 (mean±SD age 43.9±13.3 
[years]; 77% female) and 20 (47.0±12.0; 80% female) RRMS patients, respectively; con-
tent confirmation included 5 PRMS (52.6±12.5; 80% female) and 5 RSPMS (52.4±10.8; 
60% female) patients. Saturation of concepts was reached during concept elicitation. 
Cognitive debriefing confirmed that participants understood PRO instructions, items, 
Objectives: The quality-adjusted time without symptoms and toxicity (Q-TWiST) 
methodology has been used to assess the clinical benefits (prolonged [progres-
sion-free] survival) and costs (toxicities) of oncology therapies. This study was con-
ducted to systematically review and quantitatively summarize published Q-TWiST 
assessments of cancer treatments. MethOds: A systematic search and review was 
conducted in MEDLINE to identify original studies reporting the Q-TWiST informa-
tion—including time with toxicity (TOX), time before disease progression without 
toxicity (TWiST), and time in relapse after disease progression (REL)—for all oncol-
ogy treatment groups, as available. Utilities for Q-TWiST were also captured; when 
a base case for utilities was not selected in a study, the following was assumed: 
u(TWiST)= 1, u(REL)= 0.5, and u(TOX)= 0.5. The relative gain in Q-TWiST for active 
treatment arms was calculated as the difference in Q-TWiST divided by mean 
overall survival of control arm. Relative gains ≥ 10% and ≥ 15% were considered 
to be a clinically important and clearly clinically important difference, respec-
tively. Results: Upon review of 84 initially identified articles, 39 were excluded 
for the following reasons: no Q-TWiST was reported (n= 22), not oncology-related 
(n= 13), other reasons (n= 4). Forty-five studies were included and reported a total 
of 69 Q-TWiST comparisons across 10 cancers. The most commonly used utilities 
for Q-TWiST calculation were u(TWiST)= 1, u(REL)= 0.5, u(TOX)= 0.5 (n= 28, 62.2% of 
articles). Using base-case utility values, the mean (range) Q-TWiST gain was 5.2 
(-6.8 to 61) months and the mean relative gain was 9.0% (-13.3% to 60.0%); 41.8% 
and 17.9% of studies reported relative gains ≥ 10% and ≥ 15%, respectively. Applying 
u(REL)= u(TOX)= 0.5 to comparisons with sufficient data (n= 65), the mean standard-
ized Q-TWiST gain was 5.4 (-4.1 to 61) months and mean standardized relative gain 
was 8.2% (range -15.0% to 54.5%). cOnclusiOns: This review of Q-TWiST for cancer 
therapies can serve as benchmark against which future analyses can be compared.
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Objectives: The EQ-5D is often used to measure health utilities. Uncertainty in 
the EQ-5D scoring algorithm is routinely ignored. We aim to quantify the extent of 
uncertainty in the US EQ-5D-3L scoring algorithm, which was based on data from 
3773 respondents -- largest valuation study to date. MethOds: We re-fitted the 
US scoring algorithm using the same data and functional form as was originally 
used, omitting each health state in turn and examining the error in the predicted 
mean utilities. We then used a mixed effects model, including a random effect for 
health state, adopting a Bayesian perspective to estimate the predictive distribution 
of the mean utilities for health states not included in the valuation study (which 
captured 43 of 243 health states). This allowed us to estimate uncertainty in the scor-
ing algorithm. Results: The mean absolute error for predicted mean utilities on 
cross-validation was 0.033; the mean absolute error for a perfect model, accounting 
for sampling error in the observed mean utilities, would have been 0.01. The root 
mean squared error was 0.042; for a perfect model it would have been 0.013. The 
standard deviation for the random effect for health state was 0.03, suggesting that 
the width of the confidence interval for the mean utility for a randomly selected 
health state is around 0.12. The Bayesian model indicated that the width of the 95% 
credible interval for the mean utilities varied from 0.015 to 0.45, with a median width 
of 0.18 and interquartile range of 0.15 to 0.22. cOnclusiOns: EQ-5D health utilities 
are subject to considerable uncertainty (for comparison, the MID for EQ-5D utilities 
is 0.05 to 0.08). Other countries’ scoring algorithms are based on smaller sample 
sizes and so subject to greater uncertainty. This uncertainty should be accounted 
for when using EQ-5D health utilities in economic evaluations.
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laM eMPloyMent absence and PRodUctivity scale (leaPs): fURtheR 
validation stUdies in MajoR dePRessive disoRdeR
Lam R.W.
University of British Columbia, Vancouver, BC, Canada
Objectives: There is increasing clinical and research interest in monitoring 
functional outcomes, including occupational functioning, in people with Major 
Depressive Disorder (MDD). Self-rated scales are most practical for clinical settings, 
but there are few work functioning scales that have been validated in depressed 
populations. We now report further psychometric studies of the Lam Employment 
Absence and Productivity Scale (LEAPS), a brief 10-item self-report question-
naire. MethOds: Patients meeting DSM-IV criteria for MDD completed the LEAPS 
during initial assessment and following various treatment protocols in specialist 
outpatient and family practice settings, and other scales including the self-rated 
Sheehan Disability Scale (SDS) and Health and Work Performance Questionnaire 
(HPQ), and the clinician-rated Clinical Global Impression-Improvement (CGI-I) scale. 
Standard statistical analyses for scale validation were conducted. Results: In a 
sample of 418 patients at baseline assessment, internal consistency was high, with 
Cronbach’s alpha of 0.93 (for the LEAPS total score) and 0.89 (for the productiv-
ity subscale). Convergent validity was supported by significant correlations of the 
LEAPS total score and productivity subscale with the SDS work/role item score 
(r= 0.49, 0.43, respectively, both p< 0.0001) and the HPQ Overall Performance score 
(r= -0.42, -0.53, respectively, both p< 0.0001). In a sample of 104 patients repeating the 
LEAPS within a 1 week period, excellent test-retest correlations were found (r= 0.95, 
p< 0.0001). In a sample of 176 patients assessed before and after 8 weeks of antide-
pressant treatment, the LEAPS showed good responsivity to change, with differences 
in means between CGI-I categories of Very Much Improved (LEAPS total score change 
= 10.7±5.5; productivity subscale change= 3.9±2.5), Much Improved (total= 8.3±4.5; 
subscale= 3.0±2.3) and Minimally Improved/No Change/Worse (total= 4.5±5.7; 
subscale= 1.4±2.9); differences were significant for both LEAPS total score change 
(ANOVA, F= 7.29, df= 2,83, p= 0.001) and for productivity subscale change (F= 4.07, 
df= 2,83, p= 0.021). cOnclusiOns: These data support the LEAPS as a valid, reliable 
and responsive instrument in patients with MDD.
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patients with RA. Dimensionality of the combined instrument was explored by fac-
tor analyses (exploratory and confirmatory). Two approaches were taken to address 
the multi-factor/dimensionality issue identified through factor analysis. The first 
approach was to fit a sequence of unidimensional Rasch and generalized partial credit 
(GPC) models to each factor. Model comparisons and diagnoses were performed to 
assess the adequacy of model fitting and to detect any violation of the underlying 
assumptions. The second approach was to fit a multi-dimensional IRT model to these 
items. Results: The factor analysis suggested there were three underlying factors 
in the combined PF10 and HAQ-DI. These three factors can be best characterized as 
hygiene (including 4 items from HAQ-DI and 1 from PF10), lower body activity (includ-
ing 8 items from HAQ-DI and 6 from PF10) and upper body activity (including 7 items 
from HAQ-DI and 3 from PF10). Overall, the GPC model significantly outperformed 
the Rasch model across all factors (all p-value< 0.0001), implying divergent discrimi-
nability among items within each factor. The multi-dimensional IRT improved the 
model fit but substantially increased the computation effort and sacrificed model 
interpretability. cOnclusiOns: The pooled HAQ-DI and PF10 items represent mul-
tiple domains of physical functioning. To explain the combination of these items, a 
multi-dimensional IRT model decreased model interpretability and increased com-
putation intensity compared to unidimensional models.
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how well do geneRic PRoMis fatigUe MeasURes PeRfoRM in 
RheUMatoid aRthRitis?
Bartlett S.J.1, Orbai A.M.2, Jones M.2, Bingham C.O.2
1McGill University, Montreal, QC, Canada, 2Johns Hopkins University, Baltimore, MD, USA
Objectives: Fatigue is highly prevalent, disabling, and remains under-reported and 
undertreated in rheumatoid arthritis (RA). NIH generic PROMIS®measures can assess 
PROs across health domains relevant to chronic conditions. PROMIS offers item banks 
for computer adaptive testing (CAT), paper-based short forms (SF), and single items. 
The PROMIS fatigue item bank assesses both experience (from mild tiredness to an 
overwhelming, sustained sense of exhaustion) and impact on physical, mental and 
social activities. Little is known about the feasibility and validity of PROMIS fatigue 
measures in RA trials. MethOds: Data are from the first 139 RA patients enrolled 
in an ongoing study integrating PROs into routine care at an arthritis center. Three 
PROMIS fatigue measures (CAT [5-8 items], 7-item SF, and Global Health single item) 
were administered in random order with other legacy measures. Spearman correla-
tions were used to evaluate convergent validity. Results: Participants were mostly 
female (81%) and white (85%), with a mean (SD) age of 56 (13), and RA duration of 12 
(9) yrs. Mean (SD) t-scores for the PROMIS CAT and SF were 54.1 (10.2) and 53.6 (8.9); 
the single item was 2.6/5 (.9). PROMIS measures correlated highly with a fatigue VAS 
(.78-.87), moderately with disease activity indicators including pain (.60-.68), patient 
global (.66-.72), physical function (.53-.69) and CDAI (.54-.65), and weakly with MD 
global (.36-.39). A dose-response relationship was evident across disease activity levels 
in all measures. cOnclusiOns: Our study contributes evidence of the feasibility of 
using PROMIS fatigue instruments in RA visits and of construct validity. While the 
PROMIS Fatigue CAT was most strongly associated with legacy measures and offers 
greater precision, the SF and single item performed adequately and are useful when 
paper or briefer versions are needed. Evaluation of responsiveness and validity across 
diverse patient groups and settings is needed.
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scale in Patients with tyPe 2 diabetes
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1Kantar Health, Epsom, UK, 2Kantar Health, Milan, Italy
Objectives: The 4-item Morisky Medication Adherence Scale (MMAS-4) and more 
recent 8-item version (MMAS-8) have both been validated and demonstrate concur-
rent validity among patients with hypertension, but the extent to which the scales 
can be compared has received little attention. This study assessed the comparability 
of adherence scores obtained with these scales in patients with type 2 diabetes (T2D) 
as well as the feasibility of integrating results across the scales using 4 items of the 
MMAS-8. MethOds: Data were taken from the 2011 and 2012 US National Health 
and Wellness Survey (NHWS). The NHWS is a large cross-sectional survey representa-
tive of the total adult population in several major markets; N~75,000/year in the 
US. A total of 13,007 respondents self-reported physician diagnosis of T2D and were 
administered MMAS-4 in 2011 or MMAS-8 in 2012. The two adherence scales were 
evaluated by comparing the frequency distributions of the MMAS scores for the two 
scales, Cronbach’s alpha and inter-item correlations, and the creation of a new 4-item 
scale including the questions in MMAS-8 that best matched the questions in MMAS-
4. Results: In T2D patients, both MMAS-4 and -8 scores are Poisson-like distributed, 
with median at zero (high adherence) for MMAS-4 and at 1 (medium adherence) for 
MMAS-8. Chronbach’s alpha was 0.55 for MMAS-4 and 0.71 for MMAS-8, while aver-
age item-test correlations were 0.65 and 0.57, respectively. The reduced 4-item scale 
created out of MMAS-8 is also Poisson-like distributed, Cronbach’s alpha was 0.62 and 
the average item-test correlation was 0.68. cOnclusiOns: Scores of the two MMAS 
show similar qualitative and quantitative characteristics, suggesting that it may be 
appropriate to integrate data sources using the two different versions, particularly 
when the responses to the subset of 4 MMAS-8 items are available. Future research 
should confirm that the scales can be integrated in different therapeutic areas.
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Objectives: The Diabetes Treatment Satisfaction Questionnaire (DTSQ), developed 
in UK English by Professor Clare Bradley, is a reliable, valid and widely used 8-item 
and response options as intended. The Fatigue Symptoms and Impacts Questionnaire-
RMS (FSIQ-RMS™) comprises 23 items organized in a conceptual framework with 2 
symptom domains (energy, muscle weakness) and 7 impact domains (daily activities, 
cognition, emotions, physical impact, self-care, sleep, social impact). As no novel 
concepts were reported by more than two patients per sub-group during content 
confirmation, the PRO was not revised. cOnclusiOns: The FSIQ-RMS™ was dem-
onstrated to be a comprehensive measure of fatigue-related symptoms and impacts 
in RMS patients, supporting initial content validity. Before it can be used in clinical 
practice or studies, final psychometric validation will be evaluated in a multicenter, 
observational trial in RMS patients.
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Objectives: Personal recovery is “a deeply personal, unique process of changing 
ones’ attitudes, values, feelings, goals, skills and/or roles…a way of living a satisfying, 
hopeful and contributing life even with the limitations caused by illness.”[Wayne, 
1993]. As more research studies attempt to assess personal recovery in the evalu-
ation of treatments for serious mental illness, an evaluation of personal recovery 
tools is necessary to assess utility, validity and applicability. Our goal was to identify 
individual measures of personal recovery that had been evaluated in schizophre-
nia. MethOds: We undertook a systematic review of the literature utilizing 9 data 
sources (PubMed, Embase, CINAHL, and others). These databases were searched 
using a systematic search strategy. The results were sub-divided into 4 categories: 
Personal Recovery, Schizophrenia & Related Disorders, Measure or Instrument, and 
Psychometric Properties or Validation and abstracted. Results: Nearly 2,000 unique 
titles/abstracts of published literature were identified through the described search 
process. These were evaluated against pre-specified criteria and abstracted. After 
review of each article, < 300 articles met the full criteria for abstraction. In these arti-
cles, 23 unique measures were identified and 18 had been used in the assessment of 
personal recovery in schizophrenia patients. Psychometric properties of these instru-
ments were then assessed for internal consistency, test-retest reliability and sensitiv-
ity to change; most had not been validated. cOnclusiOns: Measures of personal 
recovery can inform important aspects of clinical, humanistic, and economic trials 
in mental health. Validated scales for schizophrenia that are sensitive to change over 
the course of the illness and its treatment, should allow for a better understanding of 
patients’ functional disabilities, enabling more comprehensive monitoring and evalu-
ation of treatment strategies . While several recovery measures exist, most are too 
broad and are not validated for use in the schizophrenic population. Future research 
should focus on further development and validation of these measures.
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Objectives: To explore the feasibility and utility of using social media-based 
patient networks to gather qualitative data on patient reported outcome (PRO) 
concepts relevant to Chronic Lymphocytic Leukemia (CLL). MethOds: Adults with 
CLL participating as members of the PatientsLikeMe online patient community 
were invited to complete a web-based survey about their experiences with the 
condition. Open-ended survey questions elicited descriptions of CLL symptoms, 
impacts, and treatment-related perceptions. Other questions included CLL stage 
and treatment status, performance status, and demographic characteristics. Survey 
responses and interview transcripts were coded for qualitative content analysis 
using Atlas.ti. Results: Survey responses from 50 members of the PatientsLikeMe 
CLL community were coded for content analysis. The mean age of respondents 
was 60.5 years, 54.0% were female, and 96% were White. When surveyed, 20% of 
respondents were receiving current treatment. Among those not receiving treat-
ment, the majority (77.5%) were treatment naïve, while another 20% were in remis-
sion. The majority of patients (78.0%) reported experiencing at least 1 symptom and 
17% of patients reported their symptoms required them to be in bed for up to 50% 
of their waking day. Among 50 patients, 369 descriptions of CLL symptoms were 
coded. Fatigue was the most frequently-expressed symptom (described by 40% of 
respondents), followed by tiredness (38%), night sweats (38%), swollen lymph nodes 
(32%), and frequent infections (28%). Among impacts of CLL, worry and fear (66% of 
respondents), depressed feelings (52%), and work limitations (50%) were noted most 
frequently. cOnclusiOns: Survey results identified constitutional symptoms of 
CLL included in existing PRO instruments and the literature. These findings suggest 
that qualitative data obtained through social media applications can be potentially 
useful in supporting concept identification for newly-developed PRO instruments. 
Further research is needed to identify whether the results can support content 
validity in the same way as established qualitative research methods.
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Objectives: To explore the dimensionality of the PF construct when HAQ-DI and PF10 
items are combined into a single instrument. MethOds: Item Response Theory (IRT) 
was used to analyze data from a phase 3, randomized, placebo-controlled study in 
